|
|||||
|
|
Advances Personalized Nutrition with Bioniq launch; CFO John DeSimone to Retire at Year-End; Scott Schaefer Named Successor
LOS ANGELES--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF) today reported financial results for the second quarter ended June 30, 2026:



“This quarter marks an important milestone in the execution of our personalized nutrition strategy with the launch of Bioniq in Europe and the United States. We are bringing our vision to life and expanding the value we create for customers.”
- Stephan Gratziani, CEO
Highlights
Second Quarter 2026
Recent Developments
Outlook
1 Non-GAAP measure. Refer to Schedule A – “Reconciliation of Non-GAAP Financial Measures” for a detailed reconciliation of these measures to the most directly comparable U.S. GAAP measure for historical periods, as applicable, and a discussion of why the Company believes these non-GAAP measures are useful and certain information regarding non-GAAP guidance. |
2 Non-GAAP measure. Refer to Schedule A – “Reconciliation of Non-GAAP Financial Measures” for a discussion of why the Company believes adjusting for the effects of foreign exchange is useful. |
Management Commentary
Herbalife reported second quarter 2026 net sales of $1.3 billion, up 5.4% year-over-year, including 40 basis points of foreign currency (“FX”) headwinds. On a constant currency basis2, net sales increased 5.8% year-over-year for the quarter. This was the Company’s fourth consecutive quarter of year-over-year net sales growth on both a reported and constant currency basis.
Gross profit margin was 77.7% in the second quarter, compared to 78.0% in the prior year period. On a year-over-year and approximate basis, the change primarily reflects 47 basis points of sales mix pressure, 22 basis points of higher other costs, 20 basis points from higher inventory write-downs and 9 basis points from cost changes related to self-manufacturing and sourcing. These impacts were partially offset by 64 basis points of pricing benefits.
For the quarter, net loss attributable to Herbalife was $(26.3) million, with net loss margin of 2.0%, and adjusted net income1 of $53.3 million. Adjusted EBITDA1 of $166.6 million includes approximately $7.6 million of FX headwinds year-over-year, with adjusted EBITDA1 margin of 12.6%, down 120 basis points versus the second quarter of 2025. Diluted loss per share was $(0.25), with adjusted diluted EPS1 of $0.51, which includes a $0.04 year-over-year FX headwind.
Net cash provided by operating activities was $32.9 million and $146.7 million for the three and six months ended June 30, 2026, respectively. Capital expenditures were $11.3 million and $22.2 million for the three and six months ended June 30, 2026, respectively, and capitalized SaaS implementation costs were approximately $8 million and $18 million, respectively. The Company expects to incur total capitalized SaaS implementation costs of approximately $35 million to $55 million for the full year of 2026, which are not included in capital expenditures.
“Our net sales and EBITDA results for the second quarter were at the high end of previously issued guidance,” said John DeSimone, Chief Financial Officer. “While the recent strengthening of the U.S. dollar has resulted in additional foreign exchange headwinds affecting our reported outlook for the back half of the year, our constant currency outlook remains consistent with the expectations we shared last quarter.”
Following the first 2026 Extravaganza events in India in April, the Company hosted additional events in Uzbekistan, China, Panama, Singapore, Poland, and the United States. To date, the 2026 events have attracted over 110,000 attendees, reflecting strong distributor engagement and continued demand for in-person training, recognition and business development opportunities. In conjunction with the EMEA and U.S. Extravaganzas, the Company launched Bioniq GO, entering its next generation of personalized products, matching customers to one of forty formulas, across eleven European markets and the U.S., with additional markets to follow later in 2026. In addition, the Company is now offering distributors, customers and preferred members in the newly-launched European markets the option to subscribe to automatic monthly deliveries of Bioniq GO.
Our global Fuel Like Ronaldo campaign brought our personalized nutrition philosophy to life by highlighting the daily habits behind Cristiano Ronaldo’s performance. The global campaign reached consumers worldwide across social media, digital, print and broadcast media, as well as in-person fan fest activations around a major sporting event, creating new opportunities to engage consumers and support our distributors around the world.
Recent Developments
At the North America Extravaganza in July, the Company delivered the next release of its Pro2col™ platform as part of its extended beta program, introducing a new user experience, enhanced features, and integration with blood test diagnostics, rooted in direct distributor feedback received since initiation of the beta program. Alongside the platform updates, the Company began an early beta of at-home blood biomarker diagnostics with a select group of distributors.
In July, the Company also launched two new products under Life I/O, its recently launched healthy lifespan brand. Helio is a daily, all-in-one super shake formulated with foundational and trending ingredients like protein, fiber, methylated B vitamins, creatine, and superfood, adaptogen, and polyphenol blends for everyday health and wellness.* Stemming from its acquisition of Pruvit, Activate Energy marks the Company’s channel-exclusive entry into the exogenous ketones market, containing D-isomer BHB ketones.
CFO Transition
As announced in a separate press release today, Scott Schaefer will succeed John DeSimone as CFO, as part of a planned transition, effective January 1, 2027. Mr. DeSimone will retire, effective December 31, 2026.
“We delivered a fourth consecutive quarter of year-over-year net sales growth, and we continue to expect net sales growth for the remainder of the year,” said Stephan Gratziani. “This momentum reflects the resilience of Herbalife and has us poised to successfully carry out our long-term growth strategy. John DeSimone played an impactful role in laying this foundation, and I am grateful to him for his leadership and partnership. I am confident Scott Schaefer’s financial expertise and strategic perspective will help propel us in our next chapter.”
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Second Quarter 2026 Key Metrics
Regional Net Sales and FX Impact
| Reported Net Sales |
| YoY Growth (Decline) | ||
$ million | Q2 ‘26 | Q2 ‘25 |
| including FX | excluding FX2 |
North America | 273.0 | 272.4 |
| 0.2% | 0.2% |
Latin America | 245.0 | 210.2 |
| 16.6% | 8.2% |
EMEA | 277.8 | 287.9 |
| (3.5)% | (5.6)% |
Asia Pacific | 470.6 | 408.6 |
| 15.2% | 23.1% |
China | 60.4 | 80.0 |
| (24.5)% | (29.0)% |
Worldwide | 1,326.8 | 1,259.1 |
| 5.4% | 5.8% |
| Reported Net Sales |
| YoY Growth (Decline) | ||
$ million | YTD ‘26 | YTD ‘25 |
| including FX | excluding FX2 |
North America | 520.6 | 526.8 |
| (1.2)% | (1.2)% |
Latin America | 487.0 | 416.9 |
| 16.8% | 7.5% |
EMEA | 552.6 | 561.2 |
| (1.5)% | (6.0)% |
Asia Pacific | 966.4 | 831.1 |
| 16.3% | 21.9% |
China | 117.4 | 144.8 |
| (18.9)% | (23.3)% |
Worldwide | 2,644.0 | 2,480.8 |
| 6.6% | 5.6%
|
Outlook
Third Quarter 2026 Guidance
$ million | Net Sales | Adjusted EBITDA1 | CapEx |
Reported | +0.5% to +4.5% YoY | 160 – 180 | 15 – 25 |
Constant Currency(a) | +1.5% to +5.5% YoY | 165 – 185 |
|
Q3 ‘25 Actuals | 1,273.7 | 163.0 12.8% margin | 20.8 |
Full-Year 2026 Guidance – Revised
$ million | Net Sales | Adjusted EBITDA1 | CapEx |
Reported | +2.5% to +5.5% YoY | 670 – 690 | 50 – 70 |
Previous Guidance (May 6 ’26) | +1.5% to 5.5% YoY | 675 – 705 | 50 – 80 |
Constant Currency(a) | +2.5% to +5.5% YoY | 690 – 710 |
|
Previous Guidance (May 6 ’26) | +1.0% to +5.0% YoY | 675 – 705 | |
FY ‘25 Actuals | 5,037.5 | 657.6 13.1% margin | 80.4 |
(a) | Non-GAAP Measure. Represents projections using U.S. dollars at Q3 ‘25 and FY ‘25 average FX rates, respectively, and adjusting for other FX related impacts. Refer to Schedule A – “Reconciliation of Non-GAAP Financial Measures” for a discussion of why the Company believes adjusting for the effects of foreign exchange is useful and non-GAAP guidance. |
Guidance Assumptions
Additional FY 2026 Expectations – Revised
Earnings Webcast and Conference Call
Herbalife’s senior management team will host an audio webcast and conference call to discuss its second quarter 2026 financial results on Wednesday, August 5, 2026, at 5:30 p.m. ET (2:30 p.m. PT).
The audio webcast will be available at the following link: https://edge.media-server.com/mmc/p/6vz6bf9d
Participants joining via the conference call may obtain the dial-in information and personal PIN to access the call by registering at the following link:
https://register-conf.media-server.com/register/BI6c9d643b8ab14a798e591c1cf18bbc2e
Senior management also plans to reference slides during the webcast and call, which will be available under the Investor Relations section of Herbalife’s website at https://ir.herbalife.com, where financial and other information is posted from time to time. The webcast will also be available at the same website, along with a replay of the webcast following the completion of the event and for three months thereafter.
About Herbalife Ltd.
Herbalife (NYSE: HLF) is a premier health and wellness company, community and platform that has been changing people's lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle to live their best life.
For more information, visit https://ir.herbalife.com.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management, including for future operations, capital expenditures, or share repurchases; any statements concerning proposed new products, services, or developments; any statements regarding future economic conditions or performance; any statements of belief or expectation; and any statements of assumptions underlying any of the foregoing or other future events. Forward-looking statements may include, among others, the words “may,” “will,” “estimate,” “intend,” “continue,” “believe,” “expect,” “anticipate” or any other similar words.
Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results or outcomes could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties, many of which are beyond our control. Important factors that could cause our actual results, performance and achievements, or industry results to differ materially from estimates or projections contained in or implied by our forward-looking statements include the following:
Additional factors and uncertainties that could cause actual results or outcomes to differ materially from our forward-looking statements are set forth in the Company’s filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission on February 18, 2026, including under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in our Consolidated Financial Statements and the related Notes included therein. In addition, historical, current, and forward-looking sustainability-related statements may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions that are subject to change in the future.
Forward-looking statements in this release speak only as of the date hereof. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
Results of Operations
| Herbalife Ltd. and Subsidiaries | ||||||||||||||||
| Condensed Consolidated Statements of Income (Loss) | ||||||||||||||||
| (in millions, except per share amounts) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2026 | 2025 | 2026 | 2025 | |||||||||||||
(unaudited) | ||||||||||||||||
| Net sales | $ | 1,326.8 |
| $ | 1,259.1 |
| $ | 2,644.0 |
| $ | 2,480.8 |
| ||||
| Cost of sales |
| 296.3 |
|
| 276.9 |
|
| 587.4 |
|
| 542.1 |
| ||||
| Gross profit |
| 1,030.5 |
|
| 982.2 |
|
| 2,056.6 |
|
| 1,938.7 |
| ||||
| Selling expenses (1) |
| 466.0 |
|
| 445.9 |
|
| 927.8 |
|
| 879.3 |
| ||||
| General and administrative expenses (1) |
| 436.2 |
|
| 408.5 |
|
| 867.6 |
|
| 808.8 |
| ||||
| Other operating income (2) |
| - |
|
| (4.8 | ) |
| (5.5 | ) |
| (4.8 | ) | ||||
| Operating income |
| 128.3 |
|
| 132.6 |
|
| 266.7 |
|
| 255.4 |
| ||||
| Interest expense, net |
| 37.4 |
|
| 53.6 |
|
| 84.2 |
|
| 105.6 |
| ||||
| Other expense, net (3) |
| 94.6 |
|
| - |
|
| 94.6 |
|
| - |
| ||||
| (Loss) income before income taxes |
| (3.7 | ) |
| 79.0 |
|
| 87.9 |
|
| 149.8 |
| ||||
| Income taxes |
| 22.8 |
|
| 29.8 |
|
| 53.2 |
|
| 50.2 |
| ||||
| Net (loss) income | $ | (26.5 | ) | $ | 49.2 |
| $ | 34.7 |
| $ | 99.6 |
| ||||
| Net loss attributable to noncontrolling interest |
| (0.2 | ) |
| (0.1 | ) |
| (0.9 | ) |
| (0.1 | ) | ||||
| Net (loss) income attributable to Herbalife | $ | (26.3 | ) | $ | 49.3 |
| $ | 35.6 |
| $ | 99.7 |
| ||||
| (Loss) Earnings per share attributable to Herbalife: | ||||||||||||||||
| Basic | $ | (0.25 | ) | $ | 0.48 |
| $ | 0.34 |
| $ | 0.98 |
| ||||
| Diluted | $ | (0.25 | ) | $ | 0.48 |
| $ | 0.33 |
| $ | 0.97 |
| ||||
| Weighted-average shares outstanding: | ||||||||||||||||
| Basic |
| 104.5 |
|
| 102.7 |
|
| 104.0 |
|
| 102.2 |
| ||||
| Diluted |
| 104.5 |
|
| 103.3 |
|
| 107.8 |
|
| 102.8 |
| ||||
| (1) Prior period amounts were reclassified to conform to current period presentation. Refer to Schedule B – “Reclassifications” for additional details. | ||||||||||||||||
| (2) Other operating income for the six months ended June 30, 2026 and for the three and six months ended June 30, 2025 relates to certain China government grant income. | ||||||||||||||||
| (3) Other expense, net for the three and six months ended June 30, 2026 relates to loss on the extinguishment of the 2024 Credit Facility and the 2029 Secured Notes. | ||||||||||||||||
| Herbalife Ltd. and Subsidiaries | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (in millions) | ||||||||
| June 30, | December 31, | |||||||
2026 | 2025 | |||||||
| (unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 370.5 |
| $ | 353.1 |
| ||
| Receivables, net |
| 115.9 |
|
| 91.9 |
| ||
| Inventories |
| 507.7 |
|
| 511.7 |
| ||
| Prepaid expenses and other current assets |
| 174.7 |
|
| 188.0 |
| ||
| Total current assets |
| 1,168.8 |
|
| 1,144.7 |
| ||
| Property, plant and equipment, net |
| 412.5 |
|
| 447.7 |
| ||
| Operating lease right-of-use assets |
| 166.7 |
|
| 168.3 |
| ||
| Marketing-related intangibles and other intangible assets, net |
| 333.2 |
|
| 315.1 |
| ||
| Goodwill |
| 125.9 |
|
| 100.5 |
| ||
| Deferred income tax assets |
| 478.6 |
|
| 464.3 |
| ||
| Other assets |
| 172.0 |
|
| 145.3 |
| ||
| Total assets | $ | 2,857.7 |
| $ | 2,785.9 |
| ||
| LIABILITIES AND SHAREHOLDERS' DEFICIT | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 101.3 |
| $ | 99.8 |
| ||
| Member compensation liabilities |
| 378.0 |
|
| 402.4 |
| ||
| Current portion of long-term debt |
| 12.0 |
|
| 20.9 |
| ||
| Other current liabilities |
| 482.2 |
|
| 489.8 |
| ||
| Total current liabilities |
| 973.5 |
|
| 1,012.9 |
| ||
| Non-current liabilities: | ||||||||
| Long-term debt, net of current portion |
| 2,003.7 |
|
| 1,971.7 |
| ||
| Non-current operating lease liabilities |
| 152.1 |
|
| 155.7 |
| ||
| Other non-current liabilities |
| 195.3 |
|
| 155.0 |
| ||
| Total liabilities |
| 3,324.6 |
|
| 3,295.3 |
| ||
| Commitments and contingencies | ||||||||
| Shareholders' deficit: | ||||||||
| Common shares |
| 0.1 |
|
| 0.1 |
| ||
| Paid-in capital in excess of par value |
| 334.8 |
|
| 316.0 |
| ||
| Accumulated other comprehensive loss |
| (265.3 | ) |
| (251.5 | ) | ||
| Accumulated deficit |
| (544.1 | ) |
| (579.7 | ) | ||
| Total Herbalife shareholders' deficit |
| (474.5 | ) |
| (515.1 | ) | ||
| Noncontrolling interest |
| 7.6 |
|
| 5.7 |
| ||
| Total shareholders' deficit |
| (466.9 | ) |
| (509.4 | ) | ||
| Total liabilities and shareholders' deficit | $ | 2,857.7 |
| $ | 2,785.9 |
| ||
| Herbalife Ltd. and Subsidiaries | |||||||||
| Condensed Consolidated Statements of Cash Flows | |||||||||
| (in millions) | |||||||||
| Six Months Ended June 30, | |||||||||
2026 | 2025 | ||||||||
| (unaudited) | |||||||||
| Cash flows from operating activities: | |||||||||
| Net income | $ | 34.7 |
| $ | 99.6 |
| |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||
| Depreciation and amortization |
| 60.8 |
|
| 61.2 |
| |||
| Share-based compensation expenses |
| 20.7 |
|
| 22.0 |
| |||
| Non-cash interest expense |
| 7.0 |
|
| 8.2 |
| |||
| Deferred income taxes |
| (13.9 | ) |
| (22.7 | ) | |||
| Inventory write-downs |
| 12.0 |
|
| 14.9 |
| |||
| Foreign exchange transaction loss |
| 2.1 |
|
| 1.9 |
| |||
| Loss on extinguishment of debt |
| 94.6 |
|
| - |
| |||
| Other |
| 1.8 |
|
| (0.8 | ) | |||
| Changes in operating assets and liabilities: | |||||||||
| Receivables |
| (23.7 | ) |
| (22.4 | ) | |||
| Inventories |
| (11.8 | ) |
| (21.9 | ) | |||
| Prepaid expenses and other current assets |
| 17.1 |
|
| 22.5 |
| |||
| Accounts payable |
| - |
|
| 16.0 |
| |||
| Member compensation liabilities (1) |
| (21.6 | ) |
| (22.3 | ) | |||
| Other current liabilities (1) |
| (15.1 | ) |
| (54.6 | ) | |||
| Other |
| (18.0 | ) |
| (5.4 | ) | |||
| Net cash provided by operating activities |
| 146.7 |
|
| 96.2 |
| |||
| Cash flows from investing activities: | |||||||||
| Purchases of property, plant and equipment |
| (22.2 | ) |
| (41.1 | ) | |||
| Acquisition of business and assets |
| (10.0 | ) |
| (25.5 | ) | |||
| Other |
| (0.6 | ) |
| (2.8 | ) | |||
| Net cash used in investing activities |
| (32.8 | ) |
| (69.4 | ) | |||
| Cash flows from financing activities: | |||||||||
| Borrowings from senior secured credit facility and other debt |
| 603.5 |
|
| 270.8 |
| |||
| Principal payments on senior secured credit facility and other debt |
| (613.9 | ) |
| (282.1 | ) | |||
| Proceeds from senior secured notes due 2033 |
| 800.0 |
|
| - |
| |||
| Repayment of senior secured notes due 2029 |
| (849.0 | ) |
| - |
| |||
| Repayment of senior notes due 2025 |
| - |
|
| (115.0 | ) | |||
| Debt issuance costs |
| (19.7 | ) |
| (0.1 | ) | |||
| Share repurchases |
| (10.0 | ) |
| (6.8 | ) | |||
| Other |
| 8.4 |
|
| 0.8 |
| |||
| Net cash used in financing activities |
| (80.7 | ) |
| (132.4 | ) | |||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash |
| (15.1 | ) |
| 11.1 |
| |||
| Net change in cash, cash equivalents, and restricted cash |
| 18.1 |
|
| (94.5 | ) | |||
| Cash, cash equivalents, and restricted cash, beginning of period |
| 375.3 |
|
| 438.1 |
| |||
| Cash, cash equivalents, and restricted cash, end of period | $ | 393.4 |
| $ | 343.6 |
| |||
| (1) Prior period amounts were reclassified to conform to current period presentation. Refer to Schedule B – “Reclassifications” for additional details. | |||||||||
| |||||||||
Media Contact:
Miguel Lopez-Najera
Director, Global Corporate Communications
miguellope@herbalife.com
Investor Contact:
Samantha Holway
Vice President, Head of Investor Relations
samanthagou@herbalife.com
| 5 hours | |
| 5 hours | |
| Jul-20 | |
| Jul-20 | |
| Jul-13 | |
| Jul-01 | |
| Jun-03 | |
| Jun-02 | |
| May-15 | |
| May-08 | |
| May-07 | |
| May-06 | |
| Apr-30 | |
| Apr-29 | |
| Apr-15 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite